Accumulation of urate crystals and subsequent inflammation are the major cause of pathogenesis of gout. Two pro inflammatory cytokines IL17A and IL18 are upregulated in the serum of gout patients and plays a major role in promoting inflammation. Inhibition of these cytokines by plant phytochemicals would reduce the severity of inflammation in gout. In the present study, in silico analysis of inhibition of IL17A and IL18 by 10 plant phytochemicals were studied using the AutoDock 4.2 based on the principles of Lamarckian genetic algorithm. The results revealed a binding energy in the range of −6.32 kcal/mol to −3.5 kcal/mol and interacted with the amino acids in active pocket of IL17A and IL18. Among all the compounds, syringaresinol showing the least binding energy of −6.05 kcal/mol with IL17A and −6.32 kcal/mol with IL18. The control drug, allopurinol showed a binding energy of −3.32 and −3.18 kcal/mol with IL17A and IL18, respectively. In addition, ADME/T properties of the compounds were also analyzed to predict their drug likeliness. This docking study can be used for developing potent inhibitors of IL17A and IL18 for the treatment of gout.
INTRODUCTION
Gout is a common chronic arthritis with every 9.5% to 13.5% per 1,000 persons getting affected (Saigal et al., 2015) . The pathophysiology of the disease is mainly due to the improper uric acid metabolism leading to the precipitation and accumulation of uric acid crystals in joints, bones, tissues, and many other organs. Hence, gout is also known as hyperuricemia (Ragab et al., 2017) . Gout is more common in male compared to female with a ratio of 4:1. However, the incidence increases in women after menopause (Doherty, 2009) . In addition to inflammation in joints, bones persons with gout are at the risk of developing chronic kidney disease, hypertension, cardiovascular diseases, metabolic disorders, and psychosis (Chiu et al., 2012; Feig et al., 2008; Gerald and Falasca, 2006; Grayson et al., 2011; Mohandas and Johnson, 2008; Soltani et al., 2013) .
Hypoxanthine and xanthine formed during purine metabolism are metabolized in the liver to uric acid by the enzyme xanthine oxidase (Kostalova et al., 2015) . Uricase, an enzyme that degrades the uric acid to soluble allantoin but humans lack this enzyme. Hence, uric acid is not degraded leading to the accumulation of insoluble uric acid crystals in joints, bones, and many other organs like kidney (El Ridi and Tallima, 2017; Roddy and Doherty, 2010) . Xanthine oxidase is the primary target to inhibit uric acid formation and in the treatment of Gout. Other main biomarkers in gout are interleukin (IL) 17A and IL18, proinflammatory cytokines that are upregulated in the serum of gout patients (Cavalcanti et al., 2016; Liu et al., 2018) . These cytokines are also targets in many other diseases; IL17A is the major target in many other diseases, such as psoriasis, rheumatoid arthritis, systemic lupus erythematosus, and also in many different cancers (Kirkham et al., 2014) . IL18 is mainly involved in many autoimmune diseases (Sedimbi et al., 2013) .
In gout patients, IL17A binds to its receptor leading to chemokine release . Monoclonal antibody, secukinumab is the only one approved IL-17A inhibitor at present (Frieder et al., 2018) . Drugs to treat IL18, another major proinflammatory cytokine upregulated in gout are currently under investigation. Targetting these cytokines with chemical drug can be effective, however, may lead to many side effects. Hence, identification of plant-based compounds with IL17A and IL18 inhibitory potential can be an important breakthrough in the treatment of Gout. This is the first In silico study to find the binding potential of plant-based medicinal compounds to proinflammatory cytokines IL17A and IL18, important biomarkers in gout. The results from this study can be a foundation for developing new drugs for Gout treatment.
MATERIALS AND METHODS

Macromolecules structure retrieval
The structure of IL17A-PDB ID:4HR9 and IL18-PDB ID: 3WO2 were retrieved from Protein Data Bank (PDB) (Huang et al., 2015) . PDB is a database that contains the data of experimental structures of proteins and nucleic acids. Structure of IL7A was a homodimer (chain A and B) and IL18 3WO2 was homotetramer (chain A, B, C, and D). Only chain A was used for docking studies. Other chains and water molecules were removed using PyMol (Fig. 1 ). PyMol is a useful open source software tools to perform molecular graphics (Yuan et al., 2017) Ligand structure retrieval Eleven plant-based molecules: carvacrol, thymol, thiamine, riboflavin, limonene, diadzein, genistein, canthin-6-one, syriacusin A, syringaresinol, and gossypin with potential pharmaceutical and medicinal benefits were chosen for the ligand protein docking study. The docking study was performed against a control drug Allopurinol, prescribed to gout patients to reduce gout attacks. The structures of the ligand molecules and the control drug Allopurinol were retrieved from Pubchem database. Pubchem contains information about chemical compounds their structure, molecular formula, molecular weight, etc. (Kim et al., 2015) . The structures were retrieved in SDF format and were changed to PDB format using PyMol. The structure and medicinal properties of the ligands are listed in Table 1 .
Drug scan
All the ligands were tested for their drug potential based on Lipinski's rule of five. Molinspiration (http://www. molinspiration.com/cgi-bin/properties) was used for calculating Lipinski's properties. Lipinski's rule mainly determine the molecular attributes, such as molecular weight, logP, number of hydrogen bond acceptors, and number of hydrogen bond donors. Any ligand showing violations in Lipinski's rule were eliminated from further studies (Lipinski et al., 2012) .
Active site prediction
Amino acids involved in active pocket formation were determined using Computed Atlas for Surface Topography of proteins (CASTp). CASTp is a very easy and useful web-based tool for determining the topology and active site pockets in the proteins (Dundas et al., 2006) . Active site determination is important to set the grid box at before docking.
Docking and visualization
AutoDock 4.2 was used for docking of ligands to the proteins. AutoDock is the fully automated docking software tool most widely used to study the protein ligand binding and interactions (Morris et al., 2009) . Protein molecule was initially fixed by adding polar hydrogen, kollman charges (Azam and Abbasi, 2013) . Ligand molecule was added with gasteiger charges (Karunakar et al., 2014) . Autodock 4.2 allows setting a specific target site with the help of grid box. The X, Y, and Z dimensions were set to 40*40*40, the X center, Y center, and Z center were adjusted based on the active site of the proteins (Adejoro et al., 2016) . The output for ligand conformations were analyzed using stochastic Lamarckian genetic algorithm (Morris et al., 1998) . The least negative ∆G indicates a strong binding and favorable conformation for the ligand and the protein interaction (Afriza et al., 2018) . The 3D visualization of docked structures was performed using graphical user interface, Discovery studio (Kemmish et al., 2017) . Protein-ligand interactions, structure and ligand designing are few facilities available in Discovery studio (Meenambiga et al., 2018) 
ADME/T prediction
Absorption, distribution, metabolism, excretion, and toxicity (ADMET) of the ligands are their pharmacokinetic properties and are needed to be evaluated to determine their activity inside the body. The ADMET properties of the ligands were analyzed using admetSAR, an online ADMET prediction tool (http://lmmd.ecust.edu.cn:8000/) (Cheng et al., 2012) .
RESULTS AND DISCUSSION
Globally, Gout incidence and prevalence is continuously increasing with people aged above 30 years which is getting greatly affected. In addition to joint pains, Gout is also associated with organ failure due to the accumulation of uric acid crystals in the organs. Serum levels of proinflammatory cytokines IL17a and IL18 are upregulated in Gout patients, leading to inflammation and pain. Many plant-based herbal solutions are used for gout treatments for many decades. In this study, 11 plant compounds with potential medicinal and pharmaceutical potential were chosen for their ability to inhibit IL17A and IL 18. The structure of these ligands was obtained from pubchem (Table 1 ). The structure of IL17a and IL18 were retrieved from PDB. Any extra chains and water molecules were removed from the proteins using PyMol and the resulting protein file was saved as PDB file (Fig. 1) .
For in silico analysis of plant compounds, the drug potential of all the ligands was tested using Lipinski's rule of five. Molinspiration server was used to analyze the molecular parameters of the ligands in the Lipinski's rule. The results include the molecular weight, no of hydrogen donors, acceptors, and lipophilicity of the ligand molecules. Out of the 11 Badi et al., 2017) compounds studied, 10 compounds cleared Lipinski's rule of five, except gossypin, which showed two violations; hence, the compound was eliminated from further docking analysis. Log p value indicates the hydrophilic and hydrophobic nature of the ligands. Only thiamine, riboflavin had negative log p score indicating that these compounds are highly hydrophilic in nature (Table 2) . Active site pockets in IL17A and IL18 were determined using CASTp. CASTp is a web-based tool to determine the amino acid residues in the active pocket of the proteins. CASTp results are depicted in Figure 2 for IL17A and Figure 3 for IL18. From CASTp results, only the amino acids in the active site and their positions are listed as Table 3 for IL17A and Table 4 for IL18. Autodock4.2 was used for performing docking analysis for all the 10 compounds and their binding potential with both IL17a and IL18 was analyzed. Autodock4.2 is used to analyze the affinity, binding conformations, best orientation of ligand and target (Morris et al., 2009) . The binding energy, number of hydrogen bond interactions, and amino acids involved in the interactions are tabulated in Table 5 for IL17A and Table 6 for IL18. The docking studies of the compounds with IL17A revealed that syringaresinol a polyphenolic ligand showed the lowest binding energy of −6.05 kcal/mol. With IL17A, syringaresinol formed four hydrogen bonds with Ala69, Glu68, Cys71, and Ser118 (Fig. 4A) . The anti-inflammatory potential of syringaresinol was also proved by their inhibition of iNOS, COX-2, TNF-α, IL-1β, and IL-6 by in vitro studies (Bajpai et al., 2018) . Diadzein, an isoflavone and a potential inhibitor of TNF-α (Soumyakrishnan et al., 2011) , showed a good binding energy of -5.23 kcal/mol and formed hydrogen bonds with GLU68, SER89, CYS71 with IL17A (Fig. 4B) . Canthin-6-one also proved to inhibit TNF-α and monocyte chemoattractant protein from in vitro studies (Cho et al., 2018) . In this study, canthin-6-one, showed a binding affinity of −5.06 kcal/mol with the protein IL17A (Fig. 4C) . With IL17A compounds Syriacusin A, Riboflavin, Genistein, and Thiamine showed a binding energy in the range of −4.96 kcal/mol and −4.1 kcal/mol. The ligands and their docking interactions with IL17A amino acids are shown in Figure 4D -G, respectively. Thymol and its isomer carvacrol are proved for their inhibitory actions against IL1β and TNF-α (Gholijani et al., 2014) . In this study, docking of Thymol and Carvacrol with IL17A showed binding energies in the same range with values −3.70 kcal/mol and −3.75 kcal/mol, respectively. Figure 4H and I show the interactions of thymol and carvacrol with IL17A. All the compounds used in the study showed a binding energy greater than the standard drug Allopurinol, that showed a binding energy of −3.32 kcal/mol with IL17A (Fig. 4J) With IL18 again syringaresinol showed the least binding energy of −6.32 kcal/mol and formed one hydrogen bond with Ser 118, in the active site of the protein (Fig. 5A) . Docking of Diadzein with IL18 showed a binding energy of −5.6 kcal/mol forming hydrogen bonds at ARG 104, SER118 (Fig. 5B ). Canthin-6-one, showed a binding affinity of −5.15 kcal/mol with IL18 (Fig. 5C ). Syriacusin A, Riboflavin, Genistein, and Thiamine showed a binding energy in the range between −5.14 and −3.75 kcal/mol with IL18. Figure 5D -G depicts the association of these compounds with IL18, respectively. With IL18, thymol and carvacrol gave a binding energy of −3.56 kcal/mol and −3.51 kcal/ mol. Figure 5H and I show thymol and carvacrol interactions with IL18. Allopurinol showed a binding energy of −3.18 kcal/mol with IL18 (Fig. 5J) .
All the compounds except limonene formed bonds with the amino acids in the active site pockets of IL17A and IL18. Though limonene did not form any hydrogen bond with both IL17A and IL18, it formed other interactions with the 4 amino acids in IL17A and 11 amino acids in IL18 protein. The ADMET properties of the ligands are needed to be known for determining their drug likeliness. The ADMET properties of the ligands were analyzed using admetSAR. ADMET properties for the compounds in the study were analyzed using admetSAR. All the compounds showed good human intestinal solubility (HIA), blood brain barrier (BBB) penetration. No drug was carcinogenic. Salmonella typhimurium reverse mutation assay (AMES) toxicity is a preliminary drug screening test to analyze whether the drug causes any mutation in bacteria Salmonella typhimurium. All the compounds except Canthin-6-one and Syriacusin A were AMES negative. The lethal dose (LD50) in rats was also analyzed. The results of HIA, BB penetration, LD50 values for the compounds are listed in Table 7 . 
CONCLUSION
Currently, the drugs available can only prevent gout attacks but does not treat gout. Hence, the identification of new drugs to target and treat gout is of utmost importance. In this study, many drug potential compounds from plants were studied using docking analysis against Gout inflammatory cytokines IL17a and IL18. All the compounds had a good inhibitory potential with both the cytokines. Among them, Syringaresinol, Diadzein, and Canthine 6 one showed good binding affinity with both IL17a and IL18. Hence, these compounds can be analyzed by further in vitro studies and can be a lead in the designing of potential drug in the treatment of Gout disease.
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